Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.

HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers successfully suppressed the virus in mice and discovered a way to kill infected cells ...

The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

Russia’s HIV epidemic, already severe before the invasion of Ukraine, has worsened dramatically under the pressures of war, with health authorities now facing what may become one of the country’s ...

Why a twice‑yearly injection might prove to be a good shot Lenacapavir is a first-in-class HIV drug that works by targeting ...

Younger children living with HIV with low BMI for their age were more likely than older children to fail first-line ...

The Department of Water and Sanitation (DWS) has assured the public that the presence of anti-retroviral (ARV) residues in ...

Around 10 million people globally live with the life-threatening virus HTLV-1, yet it remains a poorly understood disease ...

As a result, residues from treated wastewater can enter rivers and surface water sources, which in turn may be used for ...

The resulting show enjoyed a two-year run. After a brief hiatus, during which Hampton moved to California, the play was ...